Asset profile
NanoLithium NP03
Small molecule
Evidence outlook · lead readout
NCT05423522 · Alzheimer's Disease
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05423522: The trial randomized 72 participants to NanoLithium NP03 or placebo and used quadruple masking during the 12-week comparison period. Its primary clinical endpoint was change in the NPI-12 total score, but results were not posted, so whether the primary endpoint was met or missed is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.